Published in Nat Rev Cancer on August 01, 2006
Adjuvant PIPAC in Gastric Cancer Patients (PIPAC-OPC4) | NCT04047004
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
A tense situation: forcing tumour progression. Nat Rev Cancer (2009) 7.80
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science (2010) 6.01
Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev (2009) 4.36
Spheroid-based drug screen: considerations and practical approach. Nat Protoc (2009) 4.01
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol (2010) 2.79
Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer (2010) 2.70
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol (2012) 2.70
Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell (2012) 2.61
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol (2014) 2.43
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16
Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release (2012) 2.12
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res (2015) 2.09
Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol (2010) 2.01
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov (2010) 1.94
Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev (2008) 1.93
Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol (2010) 1.90
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Forcing form and function: biomechanical regulation of tumor evolution. Trends Cell Biol (2010) 1.77
Polymers for drug delivery systems. Annu Rev Chem Biomol Eng (2010) 1.66
Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis (2008) 1.65
Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano (2012) 1.62
Paper-supported 3D cell culture for tissue-based bioassays. Proc Natl Acad Sci U S A (2009) 1.60
Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano (2012) 1.56
3D Cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer. PLoS One (2014) 1.54
Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) (2010) 1.51
Strategies for advancing cancer nanomedicine. Nat Mater (2013) 1.48
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today (2009) 1.47
Hand-held spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration. Anal Chem (2010) 1.47
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol (2014) 1.46
Toward Localized In Vivo Biomarker Concentration Measurements. IEEE Trans Magn (2015) 1.46
Trg-deficient Salmonella colonize quiescent tumor regions by exclusively penetrating or proliferating. J Control Release (2014) 1.45
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem (2008) 1.45
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med (2015) 1.44
Synthetic tumor networks for screening drug delivery systems. J Control Release (2015) 1.43
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med (2012) 1.42
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med (2013) 1.42
Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res (2012) 1.38
Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech (2010) 1.35
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther (2008) 1.32
Imaging hallmarks of cancer in living mice. Nat Rev Cancer (2014) 1.32
Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res (2007) 1.32
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics (2013) 1.30
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol (2012) 1.30
A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics. Lab Chip (2008) 1.30
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
A systems approach for tumor pharmacokinetics. PLoS One (2011) 1.27
Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res (2010) 1.27
Measurement of magnetic nanoparticle relaxation time. Med Phys (2012) 1.27
Advances in the formation, use and understanding of multi-cellular spheroids. Expert Opin Biol Ther (2012) 1.25
The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J Theor Biol (2012) 1.25
Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer (2009) 1.23
Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. Cell Cycle (2014) 1.22
Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22
Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J (2012) 1.20
Simian virus 40 small T antigen activates AMPK and triggers autophagy to protect cancer cells from nutrient deprivation. J Virol (2009) 1.20
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther (2008) 1.19
Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine (2012) 1.18
Concurrent quantification of multiple nanoparticle bound states. Med Phys (2011) 1.17
Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov (2011) 1.17
Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer. J Appl Physiol (1985) (2009) 1.17
Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm (2008) 1.17
In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther (2011) 1.15
Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev (2013) 1.14
Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. Open Nanomed J (2011) 1.14
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer (2010) 1.14
Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol (2013) 1.13
Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol (2009) 1.13
Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. Biophys J (2009) 1.12
The dynamics of drug resistance: a mathematical perspective. Drug Resist Updat (2012) 1.12
In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles. Nat Commun (2013) 1.11
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One (2011) 1.11
Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem (2009) 1.10
Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models. Cancer Res (2011) 1.10
Evaluating the pharmacokinetics and in vivo cancer targeting capability of Au nanocages by positron emission tomography imaging. ACS Nano (2012) 1.10
Multizone paper platform for 3D cell cultures. PLoS One (2011) 1.09
Microfluidic 3D cell culture: potential application for tissue-based bioassays. Bioanalysis (2012) 1.09
Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. Proc Natl Acad Sci U S A (2013) 1.08
Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol (1985) (2012) 1.08
The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. J Transl Med (2012) 1.08
Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging. J Biomed Opt (2012) 1.07
Combinatorial peptide libraries: mining for cell-binding peptides. Chem Rev (2013) 1.07
Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol (2013) 1.05
A tumor cord model for doxorubicin delivery and dose optimization in solid tumors. Theor Biol Med Model (2009) 1.05
Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry. Anal Chem (2013) 1.05
Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta (2013) 1.04
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res (2009) 1.04
Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm (2013) 1.04
Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep (2015) 1.03
Interstitial fluid flow and drug delivery in vascularized tumors: a computational model. PLoS One (2013) 1.03
Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol (2013) 1.03
Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv (2014) 1.03
Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol (2013) 1.02
Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. Integr Biol (Camb) (2011) 1.02
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer (2005) 3.58
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res (2007) 3.41
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol (2013) 2.92
Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer (2008) 2.89
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol (2009) 2.66
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2013) 2.54
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol (2005) 2.42
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 2.33
Placebo effects in oncology. J Natl Cancer Inst (2003) 2.23
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst (2007) 2.14
When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst (2010) 2.09
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol (2012) 1.98
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med (2006) 1.88
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Screening trials are even more difficult than we thought they were. J Natl Cancer Inst (2002) 1.76
MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials (2011) 1.71
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol (2007) 1.69
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.62
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res (2006) 1.58
Trials in palliative treatment--have the goal posts been moved? Lancet Oncol (2008) 1.57
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res (2005) 1.48
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer (2009) 1.45
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
Company stock prices before and after public announcements related to oncology drugs. J Natl Cancer Inst (2011) 1.42
Mathematics in the realm of lapatinib: 500 + 500 = 1,500? J Clin Oncol (2008) 1.42
ASCO core values. J Clin Oncol (2006) 1.40
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol (2010) 1.31
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 1.27
Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol (2005) 1.26
Assessing cognitive function in cancer patients. Support Care Cancer (2006) 1.25
Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol (2008) 1.25
Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol (2008) 1.22
Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol (2010) 1.22
Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer (2014) 1.19
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol (2010) 1.18
Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer (2011) 1.16
Evaluation of treatment benefit: randomized controlled trials and population-based observational research. J Clin Oncol (2013) 1.15
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol (2008) 1.14
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer (2010) 1.14
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer (2007) 1.13
Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol (2011) 1.11
Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J Clin Oncol (2011) 1.10
Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol (2006) 1.08
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol (2013) 1.07
Ethics in oncology: consulting for the investment industry. J Clin Oncol (2007) 1.06
Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol (2007) 1.05
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol (2013) 1.05
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev (2013) 1.03
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol (2002) 1.01
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J (2013) 1.00
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys (2004) 0.98
Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology (2006) 0.98
Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell (2012) 0.96
Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting. J Clin Oncol (2004) 0.96
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer (2009) 0.95
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res (2009) 0.94
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2006) 0.93
The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 0.93
Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells. Clin Cancer Res (2005) 0.91
Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. Int J Cancer (2013) 0.91
Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia (2012) 0.91
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs (2010) 0.89
Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Mol Cancer Ther (2013) 0.89
Broadening horizons in medical management of prostate cancer. Acta Oncol (2011) 0.88
The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res (2012) 0.88
"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. J Urol (2002) 0.88
Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res Treat (2005) 0.88
The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res (2009) 0.87
Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res (2003) 0.86
Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol (2007) 0.86
Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. JAMA (2004) 0.86
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer (2002) 0.86
Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res (2002) 0.85
Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res (2013) 0.84
The transition from phase II to phase III studies. J Clin Oncol (2009) 0.84
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs (2013) 0.84
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Pharmacol (2013) 0.84
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. BMC Cancer (2012) 0.84
Phase III trials of targeted anticancer therapies: redesigning the concept. Clin Cancer Res (2013) 0.83
Physical exercise prevents suppression of hippocampal neurogenesis and reduces cognitive impairment in chemotherapy-treated rats. Psychopharmacology (Berl) (2013) 0.82
Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat (2014) 0.81
Should screen-detected breast cancers be managed differently? J Natl Cancer Inst (2005) 0.81
Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer (2002) 0.80
Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care (2009) 0.80
Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res (2005) 0.80
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs (2014) 0.80
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. Clin Cancer Res (2003) 0.80